Use este identificador para citar ou linkar para este item:
http://www.repositorio.ufop.br/jspui/handle/123456789/16105
Título: | Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. |
Autor(es): | Cardoso, Jamille Mirelle de Oliveira Brito, Rory Cristiane Fortes de Mathias, Fernando Augusto Siqueira Reis, Levi Eduardo Soares Vieira, João Filipe Pereira Ostolin, Thais Lopes Valentim Di Paschoale Andrade, Hélida Monteiro de Ramos, Guilherme Santos Frezard, Frederic Soares, Rodrigo Dian de Oliveira Aguiar Roatt, Bruno Mendes Reis, Alexandre Barbosa |
Palavras-chave: | Leishamania infantum Liposomal meglumine antimoniate Chemotherapy |
Data do documento: | 2022 |
Referência: | CARDOSO, J. M. de O. et al. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Molecular Immunology, v. 141, p. 70-78, 2022. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0161589021003217?via%3Dihub>. Acesso em: 11 out. 2022. |
Resumo: | This study compared the therapeutic potential of the chemotherapy using meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes (Nano Sbv ) and immunotherapy with anti-canine IL-10 receptor-blocking monoclonal antibody (Anti IL-10R) on canine visceral leishmaniasis (CVL). Twenty mongrel dogs naturally infected by L. infantum, displaying clinical signs of visceral leishmaniasis were randomly divided in two groups. In the first one, nine dogs received six intravenous doses of a mixture of conventional and PEGylated liposomes containing meglumine antimoniate at 6.5 mg Sb/kg/dose. In the second one, eleven dogs received two intramuscular doses of 4 mg of anti-canine IL-10 receptor-blocking monoclonal antibody. The animals were evaluated before (T0) and 30, 90, and 180 days after treatments. Our major results demonstrated that both treatments were able to maintain hematological and biochemical parameters, increase circulating T lymphocytes subpopulations, increase the IFN-γ producing T-CD4 lymphocytes, restore the lymphoproliferative capacity and improve the clinical status. However, although these improvements were observed in the initial post-treatment times, they did not maintain until the end of the experimental follow-up. We believe that the use of booster doses or the association of chemotherapy and immunotherapy (immunochemotherapy) is promising to improve the effectiveness of treating CVL for improving the clinical signs and possibly reducing the parasite burden in dogs infected with Leishmania infantum. |
URI: | http://www.repositorio.ufop.br/jspui/handle/123456789/16105 |
Link para o artigo: | https://www.sciencedirect.com/science/article/pii/S0161589021003217?via%3Dihub |
DOI: | https://doi.org/10.1016/j.molimm.2021.11.011 |
ISSN: | 0161-5890 |
Aparece nas coleções: | DEACL - Artigos publicados em periódicos |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
ARTIGO_ComparativeEvaluationMeglumine.pdf Restricted Access | 2,06 MB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.